Intapp has released a new DealCloud with Celeste plug-in for ChatGPT for Financial Services, designed to help finance firms access client, deal, and relationship records. This integration allows deal teams to leverage GPT-6 Astra's reasoning capabilities combined with financial data for research, financial modeling, and client materials. The plug-in maintains confidentiality controls and information barriers while enabling professionals to track active deals and identify key relationships within their firm's data.

Helm360 has been granted Power Partner status by Intapp, recognizing its deep expertise and reliable service in implementing Intapp solutions for law firms. This highest-tier designation underscores Helm360's commitment to client success and its strong collaborative relationship with Intapp. The status reinforces Helm360's position as a leading technology partner, promising enhanced support and faster solutions for its clients' complex technology initiatives.

Wells Fargo & Company has lowered its price target for Kimberly-Clark (NASDAQ:KMB) from $110 to $105, maintaining an "equal weight" rating, which suggests a 6.57% upside from its previous close. This pessimistic forecast comes as Kimberly-Clark's latest quarterly results missed expectations, with EPS of $1.80 against a $2.01 consensus estimate and revenue of $4.19 billion. Despite other analysts issuing varied ratings and target adjustments, the consensus among 11 analysts tracked by MarketBeat remains a "Hold" with an average target price of $117.57.

Supernus Pharmaceuticals (SUPN) announced at the Wells Fargo 21st Annual Healthcare Conference that it has successfully navigated patent losses and is now focused on growth through a broader product portfolio, new launches, and pipeline assets. The company's strategy involves both internal R&D and external transactions to offset significant revenue losses from legacy products, resulting in a nearly 25% year-over-year revenue increase and stable profitability. Key growth drivers include Qelbree for ADHD, ONAPGO for Parkinson's disease, and ZURZUVAE for postpartum depression, with a promising pipeline featuring SPN-820 and SPN-817.

IBM has partnered with NASA to launch an open-source AI model designed to analyze the Moon's surface with greater precision, achieving up to 23% better accuracy in mapping critical lunar features. Despite the technological advancement and potential for future mission planning, IBM's shares slipped slightly. While the immediate business payoff for IBM is not clear as the model is open-source, it serves as a powerful demonstration of IBM's foundation-model technology.

Elevance Health (NYSE: ELV) shares are rising after the company reaffirmed its full-year 2026 earnings guidance ahead of investor meetings. The company maintained its adjusted EPS floor of $20.10, which is slightly below analyst estimates but exceeds consensus when unfavorable one-time items are excluded. Elevance also upheld its benefit expense ratio target of 90.2% and exhibits strong technical indicators, with shares trading above major moving averages and showing upward momentum.

Intel's stock fell 4% after Piper Sandler initiated coverage with a Neutral rating and a $110 price target, citing limited near-term upside despite the company's manufacturing progress. The brokerage acknowledged Intel's efforts to improve technology and expand its foundry business but highlighted execution challenges and intense competition in the semiconductor market as concerns. These factors are expected to temper further gains for the chipmaker.

Deckers Outdoor Corp. was denied a new trial after a jury ruled in favor of retailer Quince, finding Deckers' Ultra Mini Boot design patent invalid due to indefiniteness. Deckers argued the jury was improperly instructed to decide a legal question, but the court determined that the factual dispute regarding the clarity of Deckers' design patent drawings was appropriately decided by the jury. This decision means the jury's original finding against Deckers stands.

Olema Oncology presented at Citigroup's Biopharma Back to School Summit, discussing its lead breast cancer drug candidate, palazestrant, and its clinical and commercial prospects. The company announced a delay in top-line data for its Phase III OPERA-01 study to Q1 2027, citing slower enrollment in a specific patient subset. Olema also highlighted its second program, OP-3136, and its strategic use of AI in operations, while outlining significant market opportunities for its pipeline.

The new Apple Watch Series 12 and Ultra 4 feature advanced AI capabilities like Live Rewind and Siri Recap, which record and summarize conversations. While Sound Recognition offers useful accessibility features, the Live Rewind and Siri Recap functionalities raise significant privacy concerns for corporate environments. Companies may consider banning these devices in meetings due to the risk of business secrets leaking.